Safety and efficacy of fingolimod in Iranian patients with relapsing-remitting multiple sclerosis: An open-label study

Background: Fingolimod was the first oral therapy approved for treating relapsing-remitting multiple sclerosis (RRMS) in 2010. This open-label study evaluated the safety and efficacy of fingolideR, 0.5 mg in Iranian MS patients during one-year follow-up. Methods: A multicenter, open-label, longitudi...

Volledige beschrijving

Bibliografische gegevens

Hoofdauteurs:	Rozita Doosti, Abdorreza Naser Moghadasi, Amir Reza Azimi, Shahrokh Karbalai Saleh, Masoud Etemadifar, Vahid Shaygannejad, Fereshteh Ashtari, Mohammad Hossein Harirchian, Bahaadin Siroos, Hormoz Ayramloo, Nastaran Majdinasab, Seyyed Mohammad Masood Hojjati, Nabiollah Asghari, Seyed Mohammad Baghbanian, Hamed Cheraghmakani, Mahmoud Abedini, Behnaz Sedighi, Negar Mohseni Abbas abadi, Maedeh Ghasemitabar, Sara Talebianpour, Tohid Babayi Daylari, Vahid Dana, Neda Ghaleh noie, Mohammad Ali Sahraian
Formaat:	Artigo
Taal:	Inglês
Gepubliceerd in:	Babol University of Medical Sciences 2021-04-01
Reeks:	Caspian Journal of Internal Medicine
Onderwerpen:	fingolimod multiple sclerosis safety edss
Online toegang:	http://caspjim.com/article-1-2280-en.html
Tags:	Voeg label toe Geen labels, Wees de eerste die dit record labelt!